Stockscreener 앱 받기
25.52
2.56%
-0.67
시간 외 거래:
25.52
전일 마감가:
$26.19
열려 있는:
$26.26
하루 거래량:
618.12K
Relative Volume:
0.43
시가총액:
$2.25B
수익:
-
순이익/손실:
$-151.78M
주가수익비율:
-12.39
EPS:
-2.0595
순현금흐름:
$-136.42M
1주 성능:
-4.46%
1개월 성능:
-5.41%
6개월 성능:
-17.38%
1년 성능:
+80.35%
1일 변동 폭
$25.20
$26.96
1주일 범위
$25.20
$28.19
52주 변동 폭
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
25.52 | 2.40B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | TD Cowen | Buy |
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring an 80% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
New Mineralys hires receive stock awards vesting over four years - Stock Titan
Mineralys Therapeutics Inc (MLYS) Institutional Confidence - TradingKey
Mineralys Therapeutics Inc (MLYS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mineralys Therapeutics Inc (MLYS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mineralys Therapeutics Inc (MLYS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Mineralys Therapeutics Inc (MLYS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mineralys Therapeutics, Inc. Revenue Breakdown – NASDAQ:MLYS - TradingView
MLYS|Mineralys Therapeutics Inc|Price:27.920|Chg%:+1.210 - TradingKey
MLYS|Mineralys Therapeutics Inc|Price:27.856|Chg%:+1.146 - TradingKey
Mineralys Therapeutics Inc (MLYS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mineralys Chief Commercial Officer Eric Warren disposes of $199,900 in common shares - Bitget
Form 4 Mineralys Therapeutics Inc For: 23 July By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $199k in shares - Investing.com
Mineralys (NASDAQ: MLYS) CCO sells 7,438 shares after option exercise - Stock Titan
Form 4 Mineralys Therapeutics Inc For: 21 July By Investing.com - Investing.com Australia
Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise - Stock Titan
Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares - Investing.com
Mineralys Therapeutics, Inc. (MLYS): Analyst Consensus Points to a Promising 83% Upside Potential - DirectorsTalk Interviews
Mineralys CMO David Malcom Rodman disposes of 416 common shares worth $11,036.48 - Bitget
Responsive Playbooks and the MLYS Inflection - Stock Traders Daily
Form 144 Mineralys Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (MLYS) insider schedules 416-share sale after option exercise - Stock Titan
Mineralys Executive Stock Sale Analysis - Intellectia AI
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date - The Motley Fool
What to Know About This Mineralys Insider Sale Before a December FDA Date - The Motley Fool
Mineralys Therapeutics (MLYS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Mineralys Therapeutics (MLYS) Q3 2025 earnings summary - Quartr
Mineralys therapeutics CMO Rodman sells $556,671 in shares By Investing.com - Investing.com South Africa
Mineralys therapeutics CMO Rodman sells $556,671 in shares - Investing.com UK
Form 4 Mineralys Therapeutics Inc For: 15 July By Investing.com - Investing.com South Africa
Mineralys Therapeutics CEO Jon Congleton sells $291,441 in stock By Investing.com - Investing.com South Africa
Insider Sell: CEO Jon Congleton Sells 10,700 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus
Mineralys Therapeutics (MLYS) CMO sells 20,407 shares and exercises options - Stock Titan
Mineralys Therapeutics (MLYS) CEO logs 10,700-share sale under Rule 10b5-1 plan - Stock Titan
Planned 6,349-share stock sale by Mineralys Therapeutics (NASDAQ: MLYS) - Stock Titan
Frontier tech research, news & data - MLQ.ai
Planned 14,058-share sale at Mineralys Therapeutics (NASDAQ: MLYS) - Stock Titan
Form 144 Mineralys Therapeutics For: 13 July By Investing.com - Investing.com Australia
Mineralys Therapeutics (MLYS) insider plans 10,700-share Rule 144 stock sale - Stock Titan
Mineralys Therapeutics (MLYS) insider details stock option exercise and sales - Stock Titan
Number of shareholders of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mineralys Therapeutics Inc 주식 (MLYS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Warren Eric | Chief Commercial Officer |
Jul 21 '26 |
Sale |
26.87 |
7,438 |
199,885 |
38,400 |
2.44%
0.02%
자본화:
|
볼륨(24시간):